Faron Pharmaceutical chief executive Markku Jalkanen joined Katie to talk about the company’s successful start of patient dosing in its Phase I/II study using the company’s immunotherapy asset, bexmarilimab.
“This is a brand new opening, where our focus is to treat a really bad malignancy, acute myeloid leukemia (AML),” Jalkanen told Proactive.
He adds: “It is a very exciting time for us, at the moment.”
The Faron boss talks about the significance of the study and what it could mean for the company.